Product Information
CABERGOLINE 0.5 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.2952 per EA under NDC 59762100501. Its NADAC has been published 614 times since Dec 31, 2014.
FDA first approved this application on Dec 23, 1996.
Strength
.5 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762100501
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CABERGOLINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA020664FDA Approved
12/23/1996
On Market Since
9/22/2014
Pharmacological Classes
Price Statistics
The NADAC for CABERGOLINE 0.5 MG TABLET has been published 614 times since Dec 31, 2014, and over the history we have for it it has declined 86.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2952 per EA |
|---|---|
| All-time high | $12.1817 (Apr 13, 2016) |
| All-time low | $1.0692 (Nov 20, 2024) |
| 52-week high | $1.5270 |
| 52-week low | $1.2952 |
| Median price | $2.4863 |
| Average price | $4.1690 |
| Largest weekly change | +45.5% (Nov 18, 2020) |
| Weeks tracked | 614 |
| Tracking since | Dec 31, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cabergoline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Ergot Derivative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CABERGOLINE 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CABERGOLINE 0.5 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $1.2952 per EA (NDC 59762100501), effective Sep 30, 2026.
How has the price of CABERGOLINE 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for CABERGOLINE 0.5 MG TABLET has declined 86.6%. It has been tracked across 614 weekly CMS publications since Dec 31, 2014.
What are the highest and lowest recorded NADAC prices for CABERGOLINE 0.5 MG TABLET?
Since Dec 31, 2014, the NADAC for CABERGOLINE 0.5 MG TABLET has ranged from a low of $1.0692 (Nov 20, 2024) to a high of $12.1817 (Apr 13, 2016), with a median of $2.4863 per EA.
Are there cheaper alternatives to CABERGOLINE 0.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CABERGOLINE 0.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CABERGOLINE 0.5 MG TABLET?
CABERGOLINE 0.5 MG TABLET (NDC 59762100501) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.